查看購物車
  • Simplified Chinese
  • English
抗生素和抗真菌藥物市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按藥物類別、適應症、給藥途徑、配銷通路和地理位置
市場調查報告書
商品編碼
1591395

抗生素和抗真菌藥物市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按藥物類別、適應症、給藥途徑、配銷通路和地理位置

Antibiotics and Antimycotics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Route of Administration, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 203 Pages | 訂單完成後即時交付

價格

全球抗生素和抗真菌藥物市場預計將從2023年的612億美元成長到2031年的915.4億美元；預計 2023 年至 2031 年複合年成長率為 5.2%。抗生素和抗真菌藥物市場的成長歸因於老年人口的增加、牙科疾病負擔的增加以及美容牙科需求的激增。

抗生素和抗真菌藥物是針對不同類型病原體的抗菌劑。抗生素進一步分為殺菌抗生素（青黴素類和頭孢菌素類）和抑菌抗生素（四環素類和大環內酯類），前者可殺死細菌，後者抑制細菌生長。抗生素被廣泛用於治療細菌感染，但其有效性受到抗生素抗藥性菌株的增加的挑戰。抗真菌藥物是專門為對抗真菌感染而設計的。它們透過針對真菌細胞結構或代謝的各個方面發揮作用。常見的抗黴菌藥物包括唑類（氟康唑）、多烯類（兩性黴素 B）和棘白菌素類（卡泊芬淨）。抗真菌藥物對於治療念珠菌病和曲霉病等真菌引起的疾病至關重要。

北美抗生素和抗真菌藥物市場分為美國、加拿大和墨西哥。該市場的主要推動力是細菌和真菌感染盛行率的上升、醫療保健基礎設施的發展以及用於治療此類感染的各種抗生素和抗真菌藥物的可用性。此外，主要參與者產品發布、批准和其他策略舉措的增加預計將為預測期內的市場成長創造機會。

在北美，美國是抗生素和抗真菌藥物的最大市場。美國抗生素和抗真菌藥物市場的成長是由真菌和細菌感染的日益流行以及對有效治療方案的不斷成長的需求所推動的。肺炎是美國最常見的呼吸道感染。根據 Verywell Health Journal 2024 報告，美國每年約有 150 萬成年人被診斷出患有肺炎；其中約 100 萬人入院，5 萬人因肺炎或相關併發症死亡。阿莫西林和阿奇黴素是美國門診最常使用的治療細菌感染的抗生素。此外，隨著藥物研究和技術的不斷進步，新型抗生素和抗真菌藥物的開發勢頭強勁，回應了人們對抗生素抗藥性日益成長的擔憂和對創新療法的需求。此外，人們越來越認知到抗菌藥物管理計劃的重要性，這導致人們對抗生素處方採取更謹慎的態度，從而促使人們轉向標靶治療和聯合治療。這在醫院環境中尤其明顯，院內感染發生率不斷上升，因此需要使用強效抗菌藥物。

主要參與者正在採取產品發布、產品批准和合作等策略性舉措，預計將在預測期內支持市場成長。例如，2024年4月，美國食品藥物管理局（FDA）核准Zevtera（注射頭孢比普羅美多卡利鈉）用於治療成人金黃色葡萄球菌血流感染（SAB），包括右側感染性心內膜炎和成人患有急性細菌性皮膚和皮膚結構感染（ABSSSI）。此外，2023年3月，美國FDA批准REZZAYO（注射用瑞扎芬淨）用於治療念珠菌血症和侵襲性念珠菌症。

產品開發和治療提供方法的技術進步

製藥業強調將深度學習、人工智慧（AI）和機器學習等智慧技術融入新型抗生素的開發中。研究人員正在努力建立用於識別新活性化合物的工具和平台。利用新技術發現新抗生素的能力預計將改變抗生素和抗真菌藥物開發和核准流程的整體過程。

開發針對革蘭氏陰性菌的抗生素給研究人員帶來了巨大的挑戰，許多藥物仍處於開發階段。由於營養特異性蛋白質通道（孔蛋白），這些細菌包膜的滲透性有限，限制了非必需分子（包括抗生素）跨膜的移動。考慮到細胞膜滲透性的困難，研究人員開發了一種新的計算抗生素篩選平台（CLASP），可根據孔蛋白的分析來幫助識別潛在的藥物分子。粗粒度 (CG) 解析度、先進的採樣技術和平行運算環境等優勢可最大限度地提高 CLASP 的效能。該平台可在幾個小時內為正在研究的潛在藥物分子提供完整的熱力學和動力學結果。它還有助於理解或識別產生結構-性質關係的小分子庫，以發現具有高滲透性的抗生素。

人們越來越傾向於精準醫療方法，包括根據患者的基因譜和大量人群中常見的抗藥性模式來調整抗生素治療。這樣的革命將改善藥物的功能，同時確保最小的副作用並遏制抗藥性的發展。噬菌體療法已成為另一種新方法，涉及傳統微生物治療與噬菌體的潛在組合，以靶向並消滅抗生素抗性病原體。基因編輯技術（例如 CRISPR）的最新進展有望進一步增強噬菌體療法的前景。因此，藥物開發和治療方法的技術進步預計將在未來幾年為抗生素和抗真菌藥物市場的成長帶來新的成長趨勢。

抗生素和抗真菌藥物市場：競爭格局和主要發展

輝瑞公司、諾華公司、賽諾菲公司、羅氏公司、默克公司、葛蘭素史克公司、強生公司、西普拉有限公司、拜耳公司、艾伯維公司和安斯泰來製藥公司都是在該地區營運的主要公司。

美國食品藥物管理局、美國國立衛生研究院、聯合國國際兒童緊急基金會（UNICEF）、世界衛生組織（WHO）、國家法定疾病監測系統是準備抗生素和抗真菌藥物市場時參考的主要和次要來源報告。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：抗生素和抗黴菌藥物市場格局

  • 概述
  • PEST分析

第 5 章：抗生素和抗真菌藥物市場 - 主要市場動態

  • 抗生素和抗真菌藥物市場 - 主要市場動態
  • 市場促進因素：
    • 傳染病病率增加
    • 人們對真菌感染的認知不斷增強
  • 市場限制
    • 抗菌素抗藥性、財務障礙和廣泛的監管流程
  • 市場機會
    • 持續的資助和研發計劃
  • 未來趨勢
    • 產品開發和治療提供方法的技術進步
  • 促進因素和限制的影響：

第 6 章：抗生素和抗真菌藥物市場 - 全球市場分析

  • 抗生素和抗真菌藥物市場收入，2021-2031
  • 抗生素和抗真菌藥物市場預測分析

第 7 章：抗生素和抗真菌藥物市場分析 - 按藥物類別

  • 青黴素
  • 頭孢菌素類
  • 碳青黴烯類
  • 大環內酯類
  • 氨基糖苷類
  • 奎諾酮類
  • 磺胺類藥物
  • 四環素類
  • 唑類
  • 其他

第 8 章：抗生素和抗真菌藥物市場分析 - 按適應症

  • 皮膚感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 敗血症
  • 耳朵感染
  • 胃腸道感染
  • 其他

第 9 章：抗生素和抗真菌藥物市場分析 - 按給藥途徑

  • 口服
  • 專題
  • 其他

第 10 章：抗生素和抗真菌藥物市場分析 - 按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章：抗生素和抗真菌藥物市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 英國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：抗生素和抗真菌藥物市場 - 產業格局

  • 概述
  • 抗生素和抗真菌藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第 14 章：附錄

Product Code: TIPRE00021878

The global antibiotics and antimycotics market is anticipated to grow from US$ 61.20 billion in 2023 and is projected to reach US$ 91.54 billion by 2031; it is expected to register a CAGR of 5.2% during 2023-2031. The antibiotics and antimycotics market growth is attributed to the increasing geriatric population, the growing burden of dental diseases, and the surging demand for cosmetic dentistry.

Antibiotics and antimycotics are antimicrobial agents targeting different types of pathogens. Antibiotics are further classified into bactericidal antibiotics, which kill bacteria (penicillins and cephalosporins), and bacteriostatic antibiotics, which inhibit bacterial growth (tetracyclines and macrolides). Antibiotics are widely used to treat bacterial infections, but their effectiveness is challenged by the rise of antibiotic-resistant strains. Antimycotics are specifically designed to combat fungal infections. They work by targeting various aspects of fungal cell structure or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin). Antimycotics are essential in treating conditions caused by fungi, such as candidiasis and aspergillosis.

The North America antibiotics and antimycotics market is segmented into the US, Canada, and Mexico. The market is mainly driven by the rising prevalence of bacterial and fungal infections, the presence of developed healthcare infrastructure, and the availability of a wide range of antibiotics and antimycotics for the treatment of such infections. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period.

In North America, the US is the largest market for antibiotics and antimycotics. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Technological Advancements in Product Development and Treatment Delivery Approaches

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for a potential drug molecule under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

Antibiotics and Antimycotics Market: Competitive Landscape and Key Developments

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key companies operating in the antibiotics and antimycotics market.

The US Food and Drug Administration, National Institute of Health, United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), National Notifiable Diseases Surveillance System are among the primary and secondary sources referred to while preparing the antibiotics and antimycotics market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Antibiotics and Antimycotics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Antibiotics and Antimycotics Market - Key Market Dynamics

  • 5.1 Antibiotics and Antimycotics Market - Key Market Dynamics
  • 5.2 Market Drivers:
    • 5.2.1 Increasing Prevalence of Infectious Diseases
    • 5.2.2 Growing Awareness About Fungal Infections
  • 5.3 Market Restraints
    • 5.3.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 5.4 Market Opportunities
    • 5.4.1 Ongoing Funding and Research & Development Initiatives
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 5.6 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - Global Market Analysis

  • 6.1 Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 6.2 Antibiotics and Antimycotics Market Forecast Analysis

7. Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 7.1 Penicillin
    • 7.1.1 Overview
    • 7.1.2 Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Cephalosporines
    • 7.2.1 Overview
    • 7.2.2 Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Carbapenems
    • 7.3.1 Overview
    • 7.3.2 Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Macrolides
    • 7.4.1 Overview
    • 7.4.2 Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Aminoglycosides
    • 7.5.1 Overview
    • 7.5.2 Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Quinolones
    • 7.6.1 Overview
    • 7.6.2 Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Sulfonamides
    • 7.7.1 Overview
    • 7.7.2 Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Tetracyclines
    • 7.8.1 Overview
    • 7.8.2 Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Azoles
    • 7.9.1 Overview
    • 7.9.2 Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibiotics and Antimycotics Market Analysis - by Indication

  • 8.1 Skin Infections
    • 8.1.1 Overview
    • 8.1.2 Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Respiratory Infections
    • 8.2.1 Overview
    • 8.2.2 Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Urinary Tract Infections (UTI)
    • 8.3.1 Overview
    • 8.3.2 Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Septicemia
    • 8.4.1 Overview
    • 8.4.2 Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Ear Infections
    • 8.5.1 Overview
    • 8.5.2 Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Gastrointestinal Infections
    • 8.6.1 Overview
    • 8.6.2 Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Topical
    • 9.2.1 Overview
    • 9.2.2 Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibiotics and Antimycotics Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Antibiotics and Antimycotics Market Overview
    • 11.1.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.1.2.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.1.2.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.1.2.4 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.1.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.3.1 United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.1.1 United States: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.1.2 United States: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.1.3 United States: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.1.4 United States: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.2 Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.2.1 Canada: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.2.2 Canada: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.2.3 Canada: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.2.4 Canada: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.1.3.3 Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.3.3.1 Mexico: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.1.3.3.2 Mexico: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.1.3.3.3 Mexico: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.1.3.3.4 Mexico: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Antibiotics and Antimycotics Market Overview
    • 11.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.2.1 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.2.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.2.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.2.2.4 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.2.3.1 Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.1.1 Germany: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.1.2 Germany: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.1.3 Germany: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.1.4 Germany: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.2 France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.2.1 France: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.2.2 France: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.2.3 France: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.2.4 France: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.3 Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.3.1 Spain: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.3.2 Spain: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.3.3 Spain: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.3.4 Spain: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.4 Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.4.1 Italy: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.4.2 Italy: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.4.3 Italy: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.4.4 Italy: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.5 United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.5.1 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.5.2 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.5.3 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.5.4 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.2.3.6 Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.3.6.1 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.2.3.6.2 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.2.3.6.3 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.2.3.6.4 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Antibiotics and Antimycotics Market Overview
    • 11.3.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.2.1 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.3.2.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.3.2.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.3.2.4 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.3.3.1 China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.1.1 China: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.1.2 China: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.1.3 China: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.1.4 China: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.2 Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.2.1 Japan: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.2.2 Japan: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.2.3 Japan: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.2.4 Japan: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.3 India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.3.1 India: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.3.2 India: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.3.3 India: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.3.4 India: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.4 Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.4.1 Australia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.4.2 Australia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.4.3 Australia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.4.4 Australia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.5 South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.5.1 South Korea: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.5.2 South Korea: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.5.3 South Korea: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.5.4 South Korea: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.3.3.6 Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.3.6.1 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.3.3.6.2 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.3.3.6.3 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.3.3.6.4 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
    • 11.4.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.4.2.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.4.2.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.4.2.4 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.1.2 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.1.3 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.1.4 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.2 South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 South Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.2.2 South Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.2.3 South Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.2.4 South Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.3 United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.3.2 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.3.3 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.3.4 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.4.3.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.4.3.4.2 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.4.3.4.3 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.4.3.4.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Antibiotics and Antimycotics Market Overview
    • 11.5.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
      • 11.5.2.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
      • 11.5.2.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
      • 11.5.2.4 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Brazil: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.1.2 Brazil: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.1.3 Brazil: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.1.4 Brazil: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.2 Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 Argentina: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.2.2 Argentina: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.2.3 Argentina: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.2.4 Argentina: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
      • 11.5.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Drug Class
        • 11.5.3.3.2 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Indication
        • 11.5.3.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
        • 11.5.3.3.4 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Merck & Co Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Johnson & Johnson
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Cipla Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bayer AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 AbbVie Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Astellas Pharma Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Antibiotics and Antimycotics Market Segmentation
  • Table 2. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 4. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 8. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 12. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 16. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 20. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 24. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 27. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 28. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 29. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 30. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 31. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 32. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 33. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 35. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 36. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 37. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 39. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 40. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 41. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 43. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 44. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 47. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 48. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 49. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 51. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 52. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 53. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 55. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 56. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 57. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 59. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 60. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 61. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 62. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 63. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 64. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 65. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 66. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 67. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 68. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 69. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 70. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 71. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 72. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 73. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 74. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 75. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 76. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 77. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 78. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 79. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 80. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 81. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 82. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 83. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 84. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 85. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 86. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 87. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 88. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 89. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 90. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 91. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 92. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 93. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 94. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 95. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 96. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 97. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 98. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 99. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 100. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 101. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 102. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 103. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Indication
  • Table 104. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 105. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 106. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 107. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 108. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 109. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 110. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 111. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 112. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. Antibiotics and Antimycotics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 18. Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 26. Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 30. Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. North America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 35. United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Europe: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 40. Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Asia Pacific: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 48. China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 56. Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 60. South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. South and Central America: Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 62. Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 65. Growth Strategies in Antibiotics and Antimycotics Market